Versigent (NYSE:VGNT – Get Free Report) shares traded up 10.2% during mid-day trading on Wednesday . The stock traded as high as $49.92 and last traded at $49.7680. 2,825,330 shares changed hands during trading, an increase of 7% from the average session volume of 2,647,249 shares. The stock had previously closed at $45.16.
Analyst Ratings Changes
Several equities analysts have recently issued reports on the company. Zacks Research raised Versigent to a “hold” rating in a research note on Thursday, April 16th. Wolfe Research assumed coverage on Versigent in a research note on Thursday, April 30th. They set an “outperform” rating and a $53.00 price target on the stock. Evercore reaffirmed an “outperform” rating and set a $60.00 price target on shares of Versigent in a research note on Monday, May 18th. UBS Group upped their price target on Versigent from $43.00 to $49.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Finally, TD Cowen increased their price objective on shares of Versigent from $47.00 to $49.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $45.67.
Read Our Latest Stock Analysis on Versigent
Versigent Stock Up 10.2%
Versigent (NYSE:VGNT – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The company reported $999.00 earnings per share for the quarter.
Featured Stories
- Five stocks we like better than Versigent
- Coke’s $10B India IPO Plan Pops the Top on Hidden Value
- FedEx Unboxes Billions in Post-Spinoff Value
- Marvell’s AI Moment Raises a Bigger Question for Amazon and ServiceNow
- Palo Alto Networks Accelerates Growth 31% on AI Demand
Receive News & Ratings for Versigent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versigent and related companies with MarketBeat.com's FREE daily email newsletter.
